Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2025
Rule of Two for faster access to medicines
3 April 2025 - Associate Health Minister David Seymour is welcoming Cabinet’s decision to enable medicines to be approved in ...
Posted by Michael Wonder on 03 Apr 2025
Platform clinical trials for the efficient evaluation of multiple treatments
31 March 2025 - For some medical conditions, including conditions without effective treatments, multiple promising but unproven therapies may exist, with ...
Posted by Michael Wonder on 30 Mar 2025
Bristol Myers Squibb receives positive CHMP opinion for peri-operative regimen of neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer in patients with tumour cell PD-L1 expression ≥1%
28 March 2025 - Recommendation based on Phase 3 CheckMate -77T trial showing significant event-free survival improvement when compared to neoadjuvant ...
Posted by Michael Wonder on 27 Mar 2025
American pharmaceutical boss does not support tariffs on Australian medicines
26 March 2025 - The head of one of America's largest pharmaceutical companies says he does not support tariffs on ...
Posted by Michael Wonder on 21 Mar 2025
Why US drug giants are so angry about Australia’s PBS
20 March 2025 - US pharmaceutical giants hope the protectionist Trump administration will force Australia to increase the price it pays ...
Posted by Michael Wonder on 20 Mar 2025
Australia defends PBS as US companies urge Trump to impose reciprocal tariffs
19 March 2025 - American medical giants have labelled the federal government's PBS "egregious and discriminatory" and have pressed US ...
Posted by Michael Wonder on 20 Mar 2025
Big pharma’s plea to Trump to punish Australia for cheaper medicines
19 March 2025 - American medical giants have slammed the $18 billion pharmaceutical benefits scheme in a plea to US ...
Posted by Michael Wonder on 08 Mar 2025
FDA’s accelerated approval guidance gets pushback from industry
7 March 2025 - The pharmaceutical industry has some questions regarding the US FDA's recent guidance on its accelerated approval ...
Posted by Michael Wonder on 03 Mar 2025
Supporting the development of drugs for rare diseases - the importance of regulatory transparency
1 March 2025 - Transparency regarding the information submitted to the FDA and the agency’s decision making could have far-reaching ...
Posted by Michael Wonder on 02 Mar 2025
mRESVIA RSV vaccine approved to protect patients aged 60 and over
28 February 2025 - A study found that around 4 months after vaccination, people who received the respiratory syncytial virus vaccine had ...
Posted by Michael Wonder on 26 Feb 2025
Value for private health insurance
26 February 2025 - The Australian Government has ensured Australians get value for money from their private health insurance. ...
Posted by Michael Wonder on 17 Feb 2025
Out of pocket getting out of hand - reducing the financial toxicity of rapidly approved drugs
15 February 2025 - In 2023, Teresa was diagnosed with amyotrophic lateral sclerosis. Several months later, her family started a GoFundMe ...
Posted by Michael Wonder on 15 Feb 2025
Efanesoctocog alfa approved to prevent and treat bleeding in children and adults with severe or moderate haemophilia A
14 February 2025 - The MHRA has today approved efanesoctocog alfa (Altuvoct) to be used to treat and prevent bleeding in ...
Posted by Michael Wonder on 07 Feb 2025
US FDA approves Emblaveo (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections with limited or no treatment options
7 February 2025 - Emblaveo is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the US FDA to ...
Posted by Michael Wonder on 05 Feb 2025
Izchiq vaccine approved to protect adults against Chikungunya
4 February 2025 - The MHRA has today approved the vaccine chikungunya vaccine (live) (Ixchiq) to protect adults against chikungunya disease, ...